Economic evaluation of infliximab, synthetic triple therapy and methotrexate in the treatment of newly diagnosed juvenile idiopathic arthritis

• Main Authors: Maarit Tarkiainen (Author), Pirjo Tynjälä (Author), Paula Vähäsalo (Author), Kristiina Aalto (Author), Liisa Kröger (Author), Katariina Rebane (Author), Pekka Lahdenne (Author), Janne Martikainen (Author)
• Format: Book
• Published: BMC, 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Evaluation of costs and short-term cost-effectiveness of infliximab plus methotrexate (IFX + MTX); triple therapy of hydroxychloquine, sulphasalazine, and methotrexate (TRIPLE); or methotrexate monotherapy (MTX) in patients with new-onset polyarticular juvenile idiopathic arthrit...